Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Advertising

Press Release

PD-1/PD-L1 Inhibitors Markets 2017: The First Major Wave of Immuno-Oncology - Research and Markets

Research and Markets
Posted on: 09 Nov 17

The "PD-1/PD-L1 Inhibitors: The First Major Wave of Immuno-Oncology" report has been added to Research and Markets' offering.

Since Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical) first gained Japanese regulatory approval for the treatment of metastatic melanoma in July 2014, programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) inhibitors have grown to become the leading class of immunotherapies in oncology worldwide.

Sales of the PD-1/PD-L1 therapy class have grown from $84m in 2014 to $6,292m in 2016, with five PD-1/PD-L1 inhibitors currently approved across a variety of tumor indications. Despite the success of these products, developers continue to face clinical and commercial challenges. Nonetheless, the broad applicability and strong initial success of PD-1/PD-L1 inhibitors in oncology means that companies are actively seeking ways to differentiate their products and increase their market share.

Key Topics Covered:

1 Overview of the current immuno-oncology market

  • Ongoing developments in the PD-1/PD-L1 therapy space

2 Opdivo (nivolumab; Bristol-Myers Squibb/Ono Pharmaceutical)

  • Keytruda (pembrolizumab; Merck & Co)
  • Tecentriq (atezolizumab; Roche/Chugai)
  • Imfinzi (durvalumab; AstraZeneca)
  • Bavencio (avelumab; Merck KGaA/Pfizer)

3 Challenges with PD-1/PD-L1 inhibitor development and treatment

4 An examination of:

  • Non-small cell lung cancer (NSCLC)
  • Bladder cancer

5 Looking forward: the future of immuno-oncology

For more information about this report visit https://www.researchandmarkets.com/research/nfjv7j/pd1pdl1

View source version on businesswire.com: http://www.businesswire.com/news/home/20171109005686/en/

Business Wire
www.businesswire.com

Last updated on: 09/11/2017

Advertising
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.